IGM Biosciences, Inc. (IGMS)
NASDAQ: IGMS · Real-Time Price · USD
1.380
-0.010 (-0.72%)
Feb 21, 2025, 4:00 PM EST - Market closed
IGM Biosciences Stock Forecast
Stock Price Forecast
The 7 analysts with 12-month price forecasts for IGM Biosciences stock have an average target of 6.14, with a low estimate of 1.50 and a high estimate of 22. The average target predicts an increase of 344.93% from the current stock price of 1.38.
Analyst Consensus: Hold
* Price targets were last updated on Jan 10, 2025.
Analyst Ratings
The average analyst rating for IGM Biosciences stock from 8 stock analysts is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 1 | 1 | 1 | 0 | 0 |
| Buy | 2 | 2 | 2 | 3 | 1 | 1 |
| Hold | 4 | 4 | 4 | 3 | 7 | 7 |
| Sell | 0 | 1 | 1 | 1 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 8 | 8 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| JP Morgan | JP Morgan | Sell → Hold Upgrades n/a | Sell → Hold | Upgrades | n/a | n/a | Jan 13, 2025 |
| Jefferies | Jefferies | Strong Buy → Hold Downgrades $48 → $2 | Strong Buy → Hold | Downgrades | $48 → $2 | +44.93% | Jan 10, 2025 |
| Truist Securities | Truist Securities | Hold Maintains $12 → $2 | Hold | Maintains | $12 → $2 | +44.93% | Jan 10, 2025 |
| Stifel | Stifel | Strong Buy → Hold Downgrades $27 → $2.5 | Strong Buy → Hold | Downgrades | $27 → $2.5 | +81.16% | Jan 10, 2025 |
| RBC Capital | RBC Capital | Buy → Hold Downgrades $20 → $1.5 | Buy → Hold | Downgrades | $20 → $1.5 | +8.70% | Jan 10, 2025 |
Financial Forecast
Revenue This Year
2.70M
from 2.13M
Increased by 26.85%
Revenue Next Year
6.08M
from 2.70M
Increased by 125.17%
EPS This Year
-3.46
from -4.71
EPS Next Year
-1.07
from -3.46
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 3.4M | 24.8M | 33.3M | |||
| Avg | 2.7M | 6.1M | 11.0M | |||
| Low | 2.2M | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 61.2% | 818.9% | 448.0% | |||
| Avg | 26.9% | 125.2% | 80.1% | |||
| Low | 4.3% | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -3.42 | -0.09 | -0.06 | |||
| Avg | -3.46 | -1.07 | -1.01 | |||
| Low | -3.55 | -2.00 | -2.72 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.